PCN104 Cost-Utility MODEL of Trastuzumab Emtansine (T-DM1) in HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab and a Taxane, Compared with Capecitabine PLUS Lapatinib, Trastuzumab ...

Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.08.241
https://www.valueinhealthjournal.com/article/S1098-3015(20)32497-9/fulltext
Section Title :
Section Order : 10189
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32497-9&doi=10.1016/j.jval.2020.08.241
HEOR Topics :
Tags :
Regions :